Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma

Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinomaUrothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma, Published online: 05 December 2017; doi:10.1038/nrclinonc.2017.1842017 saw the publication of clinical trial data and the approval of new treatment approaches for metastatic urothelial carcinoma. Pembrolizumab is now a well-established treatment for patients with disease progression after cisplatin, with high-level evidence supporting its superiority over second-line chemotherapy. For patients ineligible for cisplatin, atezolizumab and pembrolizumab provide meaningful clinical benefit as frontline therapies.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research